ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Nuvation Bio and Daiichi Sankyo side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Nuvation BioDaiichi Sankyo
studies on the registry20499
open to participants now638
phase 3 studies under way421
reach primary completion within a year211
programswith a study of their own in two years220

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNuvation BioDaiichi Sankyo
Phase 100%

Daiichi Sankyo: 7 of its 20 programs at phase 1

  1. DS1025Aphase 1
  2. DS3610Aphase 1
  3. DS5361Bphase 1
  4. DS9051Bphase 1
  5. valemetostatphase 1

and 2 more — sign in to see them all

35%
Phase 200%25%
Phase 3

Nuvation Bio: 2 of its 2 programs at phase 3

  1. taletrectinibphase 3
  2. safusidenibphase 3
100%

Daiichi Sankyo: 5 of its 20 programs at phase 3

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. quizartinibphase 3
  5. raludotatug deruxtecanphase 3
25%
Approved, new studies00%

Daiichi Sankyo: 3 of its 20 programs at approved, new studies

  1. bempedoic acidapproved, new study
  2. Ezetimibeapproved, new study
  3. Atorvastatinapproved, new study
15%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Nuvation Bio1 readouts · 0 phase 3···

Nuvation Bio, Feb ’27: 1 program whose next study reaches primary completion

  1. taletrectinibphase 3 · Feb 2 · NCT07742384
········
Daiichi Sankyo3 readouts · 1 phase 3·

Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion

  1. raludotatug deruxtecanphase 3 · Dec 30 · NCT04707248
····

Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion

  1. quizartinibphase 3 · May 1 · NCT03793478
····

Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trastuzumab deruxtecanphase 3 · Oct 1 · NCT05950945
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Nuvation Bio

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Daiichi Sankyo

New programs 1

  • olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionNuvation BioDaiichi Sankyo
Carcinoma, Non-Small-Cell Lungboth · compare here

Nuvation Bio in Carcinoma, Non-Small-Cell Lung: 1 program

  1. taletrectinibphase 3

Their studies: Nuvation Bio’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsboth · compare here

Nuvation Bio in Neoplasms: 1 program

  1. taletrectinibphase 3

Their studies: Nuvation Bio’s studies of Neoplasms in search

Daiichi Sankyo in Neoplasms: 1 program

  1. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Nuvation Bio 2 of 2 · Daiichi Sankyo 14 of 20 programs (13 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.